全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

1例免疫低下患者二次感染耶氏肺孢子菌肺炎的诊疗分析
Diagnosis and Treatment of an Immunocompromised Patient with Secondary Infection of Pneumocystis jirovecii Pneumonia

DOI: 10.12677/jcpm.2025.41133, PP. 948-958

Keywords: 耶氏肺孢子菌肺炎,免疫功能低下,非HIV二次感染
Pneumocystis jirovecii Pneumonia
, Low Immune Function, Non-HIV Secondary Infection

Full-Text   Cite this paper   Add to My Lib

Abstract:

耶氏肺孢子菌肺炎是一种真菌感染,最常影响免疫功能低下的人群,严重时可危及生命。通常,高危患者是那些具有改变宿主免疫的基础疾病状态的患者,例如癌症、人类免疫缺陷病毒、移植受者或正在接受免疫抑制疗法和药物治疗的患者。本文报告了一例罕见的耶氏肺孢子菌感染病例,该病例发生在免疫功能低下的患者中,且在进行正规抗感染治疗一年后二次感染耶氏肺孢子菌肺炎且合并新型冠状病毒的感染,两次诊治过程中均给予抗感染、止咳化痰等治疗,患者发热、呼吸困难等症状最终好转并出院。本文通过复习有关资料,深入探讨了免疫低下患者耶氏肺孢子菌肺炎的临床特点及肺部影像学表现,着重分析反复感染的原因,以期提高临床认识。
Pneumocystis jirovecii pneumonia is a fungal infection that most frequently affects individuals with compromised immune function and can be life-threatening in severe cases. Typically, high-risk patients are those with underlying disease conditions that modify host immunity, such as cancer, human immunodeficiency virus, transplant recipients, or patients who are undergoing immunosuppressive therapies and taking medications. This paper presents a rare instance of Pneumocystis jirovecii infection, which occurred in an immunosuppressed patient. The case was reinfected with pneumocystis jirovecii pneumonia and was complicated with novel coronavirus infection after one year of regular anti-infective treatment. Anti-infective treatment, along with cough and sputum reduction measures, were provided to the patient during both treatments. By reviewing the relevant data, the clinical characteristics and imaging findings of Pneumocystis jirovecii pneumonia in immunocompromised patients were discussed, and the causes of repeated infection were analyzed to enhance clinical understanding.

References

[1]  Mecoli, C.A., Saylor, D., Gelber, A.C., et al. (2017) Pneumocystis jiroveci Pneumonia in Rheumatic Disease: A 20-Year Single-Centre Experience. Clinical and Experimental Rheumatology, 35, 671-673.
[2]  Ricciardi, A., Gentilotti, E., Coppola, L., Maffongelli, G., Cerva, C., Malagnino, V., et al. (2017) Infectious Disease Ward Admission Positively Influences P. Jiroveci pneumonia (PJP) Outcome: A Retrospective Analysis of 116 HIV-Positive and HIV-Negative Immunocompromised Patients. PLOS ONE, 12, e0176881.
https://doi.org/10.1371/journal.pone.0176881

[3]  Bateman, M., Oladele, R. and Kolls, J.K. (2020) Diagnosing Pneumocystis jirovecii Pneumonia: A Review of Current Methods and Novel Approaches. Medical Mycology, 58, 1015-1028.
https://doi.org/10.1093/mmy/myaa024

[4]  Oren, I., Finkelstein, R., Hardak, E., Sprecher, H. and Yigla, M. (2011) Polymerase Chain Reaction-Based Detection of Pneumocystis jirovecii in Bronchoalveolar Lavage Fluid for the Diagnosis of Pneumocystis Pneumonia. The American Journal of the Medical Sciences, 342, 182-185.
https://doi.org/10.1097/maj.0b013e318210ff42

[5]  Huang, L., Cattamanchi, A., Davis, J.L., Boon, S.d., Kovacs, J., Meshnick, S., et al. (2011) HIV-Associated Pneumocystis Pneumonia. Proceedings of the American Thoracic Society, 8, 294-300.
https://doi.org/10.1513/pats.201009-062wr
[6]  Louis, M., Guitard, J., Jodar, M., Ancelle, T., Magne, D., Lascols, O., et al. (2015) Impact of HIV Infection Status on Interpretation of Quantitative PCR for Detection of Pneumocystis jirovecii. Journal of Clinical Microbiology, 53, 3870-3875.
https://doi.org/10.1128/jcm.02072-15

[7]  Limper, A.H., Offord, K.P., Smith, T.F. and Martin, W.J. (1989) Pneumocystis carinii Pneumonia: Differences in Lung Parasite Number and Inflammation in Patients with and without Aids. American Review of Respiratory Disease, 140, 1204-1209.
https://doi.org/10.1164/ajrccm/140.5.1204

[8]  Thomas, C.F. and Limper, A.H. (2004) Pneumocystis Pneumonia. New England Journal of Medicine, 350, 2487-2498.
https://doi.org/10.1056/nejmra032588

[9]  Stringer, J.R., Beard, C.B., Miller, R.F. and Wakefield, A.E. (2002) A New Name Forpneumocystis from Humans and New Perspectives on the Host-Pathogen Relationship. Emerging Infectious Diseases, 8, 891-896.
https://doi.org/10.3201/eid0809.020096

[10]  Martinez, A., Halliez, M.C.M., Moukhtar Aliouat, E., Chabé, M., Standaert-Vitse, A., Fréalle, E., et al. (2013) Growth and Airborne Transmission of Cell-Sorted Life Cycle Stages of Pneumocystis carinii. PLOS ONE, 8, e79958.
https://doi.org/10.1371/journal.pone.0079958

[11]  Ma, L., Cissé, O.H. and Kovacs, J.A. (2018) A Molecular Window into the Biology and Epidemiology of Pneumocystis spp. Clinical Microbiology Reviews, 31, 49 p.
https://doi.org/10.1128/cmr.00009-18

[12]  刘薇, 邵润霞, 刘剑波, 等. 宏基因二代测序技术在非中性粒细胞减少性侵袭性肺真菌感染病原检测中的价值[J]. 中华实用诊断与治疗杂志, 2022, 36(11): 1162-1165.
[13]  Karstaedt, A.S. and Grannum, S. (2001) Pneumocystis carinii Pneumonia in Patients with AIDS in South Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 95, 40-41.
https://doi.org/10.1016/s0035-9203(01)90327-x

[14]  Xiong, C., Lu, J., Chen, T. and Xu, R. (2022) Comparison of the Clinical Manifestations and Chest CT Findings of Pulmonary Cryptococcosis in Immunocompetent and Immunocompromised Patients: A Systematic Review and Meta-Analysis. BMC Pulmonary Medicine, 22, Article No. 415.
https://doi.org/10.1186/s12890-022-02175-9

[15]  Cheng, Q., Tang, Y., Liu, J., Liu, F. and Li, X. (2024) The Differential Diagnostic Value of Chest Computed Tomography for the Identification of Pathogens Causing Pulmonary Infections in Patients with Hematological Malignancies. Infection and Drug Resistance, 17, 4557-4566.
https://doi.org/10.2147/idr.s474229

[16]  Vogel, M.N., Brodoefel, H., Hierl, T., Beck, R., Bethge, W.A., Claussen, C.D., et al. (2007) Differences and Similarities of Cytomegalovirus and Pneumocystis Pneumonia in HIV-Negative Immunocompromised Patients—Thin Section CT Morphology in the Early Phase of the Disease. The British Journal of Radiology, 80, 516-523.
https://doi.org/10.1259/bjr/39696316

[17]  Chow, C., Templeton, P.A. and White, C.S. (1993) Lung Cysts Associated with Pneumocystis carinii Pneumonia: Radiographic Characteristics, Natural History, and Complications. American Journal of Roentgenology, 161, 527-531.
https://doi.org/10.2214/ajr.161.3.8352098

[18]  Hardak, E., Brook, O. and Yigla, M. (2010) Radiological Features of Pneumocystis jirovecii Pneumonia in Immunocompromised Patients with and without Aids. Lung, 188, 159-163.
https://doi.org/10.1007/s00408-009-9214-y

[19]  Maschmeyer, G., Helweg-Larsen, J., Pagano, L., Robin, C., Cordonnier, C. and Schellongowski, P. (2016) ECIL Guidelines for Treatment of Pneumocystis jirovecii Pneumonia in Non-HIV-Infected Haematology Patients. Journal of Antimicrobial Chemotherapy, 71, 2405-2413.
https://doi.org/10.1093/jac/dkw158

[20]  Lim, W., Suhail, M. and Diaz, K. (2021) Diagnostic Challenges of Pneumocystis Pneumonia during the COVID-19 Pandemic: A Case of a Young Patient with Ground Glass Opacities and Pulmonary Embolism on Chest CT. Case Reports in Infectious Diseases, 2021, 1-6.
https://doi.org/10.1155/2021/5669543

[21]  Pan, F., Ye, T., Sun, P., Gui, S., Liang, B., Li, L., et al. (2020) Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (Covid-19). Radiology, 295, 715-721.
https://doi.org/10.1148/radiol.2020200370

[22]  Parekh, M., Donuru, A., Balasubramanya, R. and Kapur, S. (2020) Review of the Chest CT Differential Diagnosis of Ground-Glass Opacities in the COVID Era. Radiology, 297, E289-E302.
https://doi.org/10.1148/radiol.2020202504

[23]  Bernheim, A., Mei, X., Huang, M., Yang, Y., Fayad, Z.A., Zhang, N., et al. (2020) Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. Radiology, 295, Article 200463.
https://doi.org/10.1148/radiol.2020200463

[24]  Kang, J.S. (2023) Changing Trends in the Incidence and Clinical Features of Pneumocystis jirovecii Pneumonia in Non-HIV Patients before and during the COVID-19 Era and Risk Factors for Mortality between 2016 and 2022. Life, 13, Article 1335.
https://doi.org/10.3390/life13061335

[25]  Dworkin, M.S., Hanson, D.L. and Navin, T.R. (2001) Survival of Patients with AIDS, after Diagnosis of Pneumocystis Cariniipneumonia, in the United States. The Journal of Infectious Diseases, 183, 1409-1412.
https://doi.org/10.1086/319866

[26]  Alanio, A., Dellière, S., Voicu, S., Bretagne, S. and Mégarbane, B. (2021) The Presence of Pneumocystis jirovecii in Critically Ill Patients with Covid-19. Journal of Infection, 82, 84-123.
https://doi.org/10.1016/j.jinf.2020.10.034

[27]  Blaize, M., Mayaux, J., Luyt, C., Lampros, A. and Fekkar, A. (2020) Covid-19-Related Respiratory Failure and Lymphopenia Do Not Seem Associated with Pneumocystosis. American Journal of Respiratory and Critical Care Medicine, 202, 1734-1736.
https://doi.org/10.1164/rccm.202007-2938le

[28]  Gerber, V., Ruch, Y., Chamaraux-Tran, T., Oulehri, W., Schneider, F., Lindner, V., et al. (2021) Detection of Pneumocystis jirovecii in Patients with Severe COVID-19: Diagnostic and Therapeutic Challenges. Journal of Fungi, 7, Article 585.
https://doi.org/10.3390/jof7080585

[29]  Gioia, F., Albasata, H. and Hosseini-Moghaddam, S.M. (2022) Concurrent Infection with Sars-Cov-2 and Pneumocystis jirovecii in Immunocompromised and Immunocompetent Individuals. Journal of Fungi, 8, Article 585.
https://doi.org/10.3390/jof8060585

[30]  Huang, S., Wang, Y. and Ju, S. (2021) Advances in Medical Imaging to Evaluate Acute Respiratory Distress Syndrome. Chinese Journal of Academic Radiology, 5, 1-9.
https://doi.org/10.1007/s42058-021-00078-y

[31]  Nagpal, P., Narayanasamy, S., Vidholia, A., Guo, J., Shin, K.M., Lee, C.H., et al. (2020) Imaging of COVID-19 Pneumonia: Patterns, Pathogenesis, and Advances. The British Journal of Radiology, 93, Article 20200538.
https://doi.org/10.1259/bjr.20200538

[32]  Yamada, S., Kitajima, T., Marumo, S. and Fukui, M. (2021) Legionnaire’s Disease Presenting as Bilateral Central Scotomata: A Case Report. BMC Infectious Diseases, 21, Article No. 32.
https://doi.org/10.1186/s12879-020-05715-y

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133